EvolusEOLS -0.21%71 Days Payable is 80.73 as of Mar. 2026, which is 36% above its 10-year median of 59.45. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.60 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Evolus ranks worse than 58.8% on this metric.
Evolus's average Accounts Payable for the
three
months ended in Mar. 2026 was $21.4 Mil. Evolus's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $24.2 Mil.
Hence, Evolus's Days Payable for the
three
months ended in Mar. 2026 was 80.73.
The historical rank and industry rank for Evolus's Days Payable or its related term are showing as below:
EOLS'
s Days Payable Range Over the Past 10 Years
Min: 29.36 Med: 59.45 Max: 167.47
Current: 75.06
During the past 11 years, Evolus's highest Days Payable was 167.47. The lowest was 29.36. And the median was 59.45.
EOLS's Days Payable is ranked worse than 58.8% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs EOLS: 75.06
Evolus's Days Payable
increased
from Mar. 2025 (53.02) to Mar. 2026 (80.73).
It may suggest that Evolusdelayed paying its suppliers.
Evolus Days Payable Related Terms
Evolus Days Payable Historical Data
* Premium members only.
The historical data trend for Evolus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's Days Payable distribution charts can be found below:
* The bar in red indicates where Evolus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Evolus's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a Days Payable of 80.73 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evolus and its competitors. This is 36% above median its historical median of 59.45. Over the past decade, Evolus' Days Payable has ranged from 29.36 to 167.47. According to the industry distribution chart, Evolus ranks #541 out of 920 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is Evolus' Days Payable too high?
Evolus' current Days Payable of 80.73 is 36% above median its 10-year median of 59.45. Over the past 10 years, this metric has ranged from a low of 29.36 to a high of 167.47. The Drug Manufacturers industry median Days Payable is 90.84. Evolus' value of 80.73 is 11.1% below this industry median. Based on the distribution chart, Evolus ranks #541 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Days Payable compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #541 out of 920 companies for Days Payable. This places Evolus in the lower half of its industry. The industry median Days Payable is 90.84. Evolus' value of 80.73 is 11.1% below this benchmark. Historically, Evolus' own Days Payable has ranged from 29.36 to 167.47 over the past decade. While the company's 10-year median is 59.45 vs. the industry median of 90.84, Evolus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolus's current Days Payable of 80.73 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current Days Payable is 80.73, which is 36% above median its own 10-year median of 59.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.60, compared to a current price of $7.13 — trading 47.6% below its estimated fair value. The current Days Payable is 80.73, which is 36% above median its 10-year median of 59.45 and 11.1% below the Drug Manufacturers industry median of 90.84. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Evolus (EOLS), the current Days Payable is 80.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $7.13 is trading 47.6% below its estimated GF Value™ of $13.60.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
Days Payable: 80.73 (36% above median its 10-year median of 59.45)
GF Value™: $13.60 vs. price of $7.13 (47.6% below fair value)
Industry Position: 11.1% below the Drug Manufacturers median (#541 of 920)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score
Get the complete analysis for EOLS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
